<DOC>
	<DOCNO>NCT02228096</DOCNO>
	<brief_summary>This single arm , open-label , multi-center , phase II study determine efficacy safety experimental therapy call CTL019 T-cells pediatric patient B-cell acute lymphoblastic leukemia , chemo-refractory , relapse allogeneic SCT , otherwise ineligible allogeneic stem cell transplant .</brief_summary>
	<brief_title>Study Efficacy Safety CTL019 Pediatric ALL Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<criteria>Relapsed refractory pediatric Bcell ALL : 1 . 2nd great Bone Marrow ( BM ) relapse OR 2 . Any BM relapse allogeneic SCT must &gt; 6 month SCT time CTL019 infusion OR 3 . Refractory define achieve CR ( morphology &lt; 5 % blast ) 2 cycle standard chemotherapy regimen OR 4 . Patients Philadelphia chromosome positive ( Ph+ ) ALL eligible intolerant fail 2 line tyrosine kinase inhibitor therapy ( TKI ) , TKI therapy contraindicate OR 5 . Ineligible allogeneic SCT For relapsed patient , documentation CD19 tumor expression bone marrow peripheral blood flow cytometry within 3 month study entry Adequate organ function define : 1 . Renal function define ( Calculated creatinine clearance radioisotope Glomerular Filtration Rate ( GFR ) &gt; 60 mL/min/1.73 m2 OR serum creatinine base age/gender ; 2 . Alanine Aminotransferase ( ALT ) &lt; 5 time upper limit normal ( ULN ) age ; 3 . Bilirubin &lt; 2.0 mg/dL ; 4 . Must minimum level pulmonary reserve define ≤Grade 1 dyspnea pulse oxygenation &gt; 91 % room air 5 . Left Ventricular Shortening Fraction ( LVSF ) ≥ 28 % confirm echocardiogram , Left Ventricular Ejection Fraction ( LVEF ) ≥ 45 % confirm echocardiogram MUGA Bone marrow ≥ 5 % lymphoblast morphologic assessment screen Life expectancy &gt; 12 week Age 2 time initial diagnosis age 21 time initial diagnosis Karnofsky ( age ≥ 16 year ) Lansky ( age &lt; 16 year ) performance status ≥ 50 screening Signed write informed consent assent form ( applicable ) must obtain prior study procedure Once eligibility criterion confirm , must apheresis product nonmobilized cell receive accepted manufacturing site . Note : Apheresis product ship assessed acceptance manufacturing site document confirmation eligibility criterion receive . Isolated extramedullary disease relapse Patients concomitant genetic syndrome : patient Fanconi anemia , Kostmann syndrome , Shwachman syndrome know bone marrow failure syndrome . Patients Down Syndrome exclude . Patients Burkitt 's lymphoma/leukemia ( i.e . patient mature Bcell ALL , leukemia Bcell [ surface Immunoglobulin ( sIg ) positive kappa lambda restrict positivity ] ALL , FAB L3 morphology /or MYC translocation ) Prior malignancy , except carcinoma situ skin cervix treat curative intent evidence active disease Prior treatment gene therapy product Treatment prior antiCD19/antiCD3 therapy , antiCD19 therapy Active latent hepatitis B active hepatitis C , uncontrolled infection screen HIV infection screen Presence grade 2 4 acute extensive chronic graftversushost disease ( GVHD ) The following medication exclude : 1 . Steroids : Therapeutic dos steroid must stop &gt; 72 hour prior CTL019 infusion . However , follow physiological replacement dos steroid allow : &lt; 6 12 mg/m2/day hydrocortisone equivalent ; 2 . Allogeneic cellular therapy : Any donor lymphocyte infusion ( DLI ) must complete &gt; 6 week prior CTL019 infusion ; 3 . GVHD therapy : Any drug use GVHD must stop &gt; 4 week prior CTL019 infusion ( e.g . calcineurin inhibitor , methotrexate chemotherapy drug , mycophenolyate , steroid [ see ] rapamycin , thalidomide , immunosuppressive antibody rituximab antiCD20 ( rituximab ) , antiTNF , antiIL6 , antiIL6R ; 4 . Chemotherapy : . The following drug must stop &gt; 1 week prior CTL019 infusion administer concomitantly follow lymphodepleting chemotherapy : hydroxyurea , vincristine , 6mercaptopurine , 6thioguanine , methotrexate &lt; 25 mg/m2 , cytosine arabinoside &lt; 10 mg/m2/day , asparaginase ; ii . The following drug must stop &gt; 4 week prior CTL019 infusion : salvage chemotherapy ( e.g . clofarabine , cytosine arabinoside &gt; 100 mg/m2 , anthracyclines , cyclophosphamide ) , exclude require lymphodepleting chemotherapy drug ; 5 . CNS disease prophylaxis : i. CNS prophylaxis treatment must stop &gt; 1 week prior CTL019 infusion ( e.g . intrathecal methotrexate ) . Active CNS involvement malignancy , define CNS3 per National Comprehensive Cancer Network ( NCCN ) guideline . Note : Patients history CNS disease effectively treat eligible12 . Patient participate investigational research study use investigational agent within last 30 day prior screen Pregnant nursing ( lactate ) woman . NOTE : female study participant reproductive potential must negative serum urine pregnancy test perform within 48 hour infusion Women childbearing potential , defined woman physiologically capable become pregnant male participant , unless use highly effective method contraception period 1 year CTL019 infusion ) . Highly effective contraception method include : 1 . Total abstinence ( line prefer usual lifestyle patient . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal NOT acceptable method contraception ) ; 2 . Female sterilization ( surgical bilateral oophorectomy without hysterectomy ) tubal ligation least six week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment ; 3 . Male sterilization ( least 6 month prior screen ) . For female participant study vasectomized male partner sole partner patient ; 4 . BOTH follow form contraception must utilize : . Use oral , injected implant hormonal method contraception form hormonal contraception comparable efficacy ( failure rate &lt; 1 % ) , example hormone vaginal ring transdermal hormone contraception ; ii . Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/vaginal suppository ; 5 . Use intrauterine device ( IUDs ) exclude due increase risk infection bleed population ; f ) . In case use oral contraception , woman must stable pill minimum 3 month take study treatment . 6 . Women reproductive potential ( define either &lt; 11 year age , Tanner Stage 1 , postmenopausal least 24 consecutive month ( i.e . menses ) undergo hysterectomy , salpingotomy , and/or bilateral oophorectomy ) eligible without require use contraception . Acceptable documentation include write oral documentation communicate clinician clinician 's staff one following : . Demographics show age &lt; 11 ; b . Physical examination indicate Tanner Stage 1 ; c. Physician report/letter ; d. Operative report source documentation patient record ; e. Discharge summary ; f. Follicle stimulate hormone measurement elevate menopausal range</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>